Amanda Hanson

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan et al. · Clinical Cancer Research · 2022 · 95 citations · Full text

AEBP1 expression increases with severity of fibrosis in NASH and is regulated by glucose, palmitate, and miR-372-3p

Glenn S. Gerhard, Amanda Hanson, Danielle Wilhelmsen et al. · PLoS ONE · 2019 · 74 citations · Full text

Liver Fibrosis, Immunology, Pathology +26

ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models

Amanda Hanson, Kutlu G. Elpek, Ellen Duong et al. · PLoS ONE · 2020 · 40 citations · Full text

T-regulatory Cell, Immunology, Immunoediting +20

Interleukins 7 and 15 Maintain Human T Cell Proliferative Capacity through STAT5 Signaling

Adam Drake, Mandeep Kaur, Bettina P. Iliopoulou et al. · PLoS ONE · 2016 · 30 citations · Full text

T-regulatory Cell, Immunology, Immune Regulation +17

Chemokine ligand 20 (CCL20) expression increases with NAFLD stage and hepatic stellate cell activation and is regulated by miR-590-5p

Amanda Hanson, Ignazio S. Piras, Danielle Wilhelmsen et al. · Cytokine · 2019 · 29 citations · Full text

Inflammation, Expression Increases, Signal Transduction +10